These findings indicate that AML patients with a low C/EBPα p42/p30 ratio may not respond well to venetoclax monotherapy but could benefit from combined treatment approaches that include ER stress-inducing agents [93]. This evidence concerns the gene CEBPA and acute myeloid leukemia.